Priority Medicines for Europe and the World Project

"A Public Health Approach to Innovation"


Appendices to Section 8.3

Benefit, Risk and Innovation in Pharmaceutical Research and Development: Opportunities and Issues

8.3.1      Challenge and Opportunity on the Critical Path to New Medical Products [pdf 815KB]

8.3.2      Discussion Paper: The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future 
            [pdf 488KB]

8.3.3     "Integrating and strengthening the European Research Area" - European Commission [Word 354KB]

8.3.4    Perspectives -- Cutting the Cost of Drug Development? M.D. Rawlins [pdf 138KB] 
           Reprinted by permission from Nature Reviews Drug Discovery Vol. 3 pp. 360-364 Copyright © 2004 Macmillan Magazines Ltd.

8.3.5     NICHM Study [pdf 436KB]

8.3.6     Industry criticism of NICHM Study [pdf 60KB]

8.3.7     NICHM reply to industry criticism [pdf 471KB]

8.3.8     Industry criticism of NICHM reply [pdf 42KB]

8.3.9    EMEA Comments on the project: “Priority Medicines for Europe and the world”